PD-L1在甲状腺癌中的作用机制及其在诊疗中的应用

doi:10.3760/cma.j.cn371439-20201208-00109

摘要/Abstract

摘要：

程序性死亡蛋白-1(PD-1)及其配体(PD-L1)参与免疫检查点调节,与甲状腺癌的发生和发展密切相关。PD-L1在不同类型甲状腺癌中的表达不同,可作为诊断部分肿瘤的生物标志物,PD-L1的表达与更高的肿瘤侵袭性及更高的复发风险相关,PD-1/PD-L1免疫检查点是部分甲状腺癌治疗的一个有前景的靶点。进一步探讨PD-1/PD-L1通路的作用机制、在甲状腺癌中的诊治作用及其与疗效相关的生物标志物,可为甲状腺癌的诊治提供新的思路。

关键词: 甲状腺肿瘤, 抑制因子,免疫, 预后, 程序性死亡蛋白-配体1

Abstract:

Programmed death-1 (PD-1) and programmed death-ligand 1 (PD-L1) participate in the regulation of immune checkpoint and are closely related to the occurrence and development of thyroid carcinoma. PD-L1 is expressed differently in different types of thyroid cancer and can be used as a biomarker for the diagnosis of some tumors. The expression of PD-L1 in thyroid cancersis associated with higher tumor invasiveness and higher risk of recurrence. PD-1/PD-L1 immune checkpoint is a promising target for the treatment of some thyroid cancers. Further discussion of the mechanism of PD-1/PD-L1 pathway and its role in the diagnosis and treatment of thyroid cancer and the biomarkers related to the therapeutic effect can provide new ideas for the diagnosis and treatment of thyroid cancer.

Key words: Thyroid neoplasms, Suppressor factors, immunologic, Prognosis, Programmed death-ligand 1

吴宇平, 张潇宇, 陆克义. PD-L1在甲状腺癌中的作用机制及其在诊疗中的应用[J]. 国际肿瘤学杂志, 2021, 48(9): 560-563.

Wu Yuping, Zhang Xiaoyu, Lu Keyi. Mechanism of PD-L1 in thyroid carcinoma and its application in diagnosis and treatment[J]. Journal of International Oncology, 2021, 48(9): 560-563.

参考文献 32

[1]	Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020[J]. CA Cancer J Clin, 2020, 70(1):7-30. DOI: 10.3322/caac.21590. doi: 10.3322/caac.21590
[2]	Constantinidou A, Alifieris C, Trafalis DT. Targeting programmed cell death-1 (PD-1) and ligand (PD-L1): a new era in cancer active immunotherapy[J]. Pharmacol Ther, 2019, 194:84-106. DOI: 10.1016/j.pharmthera.2018.09.008. doi: 10.1016/j.pharmthera.2018.09.008
[3]	Chowdhury S, Veyhl J, Jessa F, et al. Programmed death-ligand 1 overexpression is a prognostic marker for aggressive papillary thyroid cancer and its variants[J]. Oncotarget, 2016, 7(22):32318-32328. DOI: 10.18632/oncotarget.8698. doi: 10.18632/oncotarget.8698 pmid: 27086918
[4]	Spranger S, Gajewski TF. Impact of oncogenic pathways on evasion of antitumour immune responses[J]. Nat Rev Cancer, 2018, 18(3):139-147. DOI: 10.1038/nrc.2017.117. doi: 10.1038/nrc.2017.117 pmid: 29326431
[5]	Tanaka A, Sakaguchi S. Regulatory T cells in cancer immunotherapy[J]. Cell Res, 2017, 27(1):109-118. DOI: 10.1038/cr.2016.151. doi: 10.1038/cr.2016.151
[6]	Ahn S, Kim TH, Kim SW, et al. Comprehensive screening for PD-L1 expression in thyroid cancer[J]. Endocr Relat Cancer, 2017, 24(2):97-106. DOI: 10.1530/erc-16-0421. doi: 10.1530/erc-16-0421
[7]	Zwaenepoel K, Jacobs J, De Meulenaere A, et al. CD70 and PD-L1 in anaplastic thyroid cancer-promising targets for immunotherapy[J]. Histopathology, 2017, 71(3):357-365. DOI: 10.1111/his.13230. doi: 10.1111/his.13230 pmid: 28383817
[8]	Yin M, Di G, Bian M. Dysfunction of natural killer cells mediated by PD-1 and TIM-3 pathway in anaplastic thyroid cancer[J]. Int Immunopharmacol, 2018, 64:333-339. DOI: 10.1016/j.intimp.2018.09.016. doi: 10.1016/j.intimp.2018.09.016
[9]	Xie Z, Li X, He Y, et al. Immune cell confrontation in the papillary thyroid carcinoma microenvironment[J]. Front Endocrinol (Lausanne), 2020, 11:570604. DOI: 10.3389/fendo.2020.570604. doi: 10.3389/fendo.2020.570604
[10]	Pilli T, Toti P, Occhini R, et al. Chronic lymphocytic thyroiditis (CLT) has a positive prognostic value in papillary thyroid cancer (PTC) patients: the potential key role of Foxp3⁺ T lymphocytes[J]. J Endocrinol Invest, 2018, 41(6):703-709. DOI: 10.1007/s40618-017-0794-8. doi: 10.1007/s40618-017-0794-8 pmid: 29230715
[11]	Na KJ, Choi H. Immune landscape of papillary thyroid cancer and immunotherapeutic implications[J]. Endocr Relat Cancer, 2018, 25(5):523-531. DOI: 10.1530/erc-17-0532. doi: 10.1530/erc-17-0532
[12]	Fu G, Polyakova O, MacMillan C, et al. Programmed death-ligand 1 expression distinguishes invasive encapsulated follicular variant of papillary thyroid carcinoma from noninvasive follicular thyroid neo-plasm with papillary-like nuclear features[J]. EBioMedicine, 2017, 18:50-55. DOI: 10.1016/j.ebiom.2017.03.031. doi: 10.1016/j.ebiom.2017.03.031
[13]	Hsieh AM, Polyakova O, Fu G, et al. Programmed death-ligand 1 expression by digital image analysis advances thyroid cancer diagnosis among encapsulated follicular lesions[J]. Oncotarget, 2018, 9(28):19767-19782. DOI: 10.18632/oncotarget.24833. doi: 10.18632/oncotarget.24833 pmid: 29731981
[14]	Maletta F, Massa F, Torregrossa L, et al. Cytological features of “non-invasive follicular thyroid neoplasm with papillary-like nuclear features” and their correlation with tumor histology[J]. Hum Pathol, 2016, 54:134-142. DOI: 10.1016/j.humpath.2016.03.014. doi: 10.1016/j.humpath.2016.03.014
[15]	Bizzarro T, Martini M, Capodimonti S, et al. Young investigator challenge: the morphologic analysis of noninvasive follicular thyroid neoplasm with papillary-like nuclear features on liquid-based cyto-logy: some insights into their identification[J]. Cancer Cytopathol, 2016, 124(10):699-710. DOI: 10.1002/cncy.21777. doi: 10.1002/cncy.21777 pmid: 27717284
[16]	Dell'Aquila M, Granitto A, Martini M, et al. PD-L1 and thyroid cytology: a possible diagnostic and prognostic marker[J]. Cancer Cytopathol, 2020, 128(3):177-189. DOI: 10.1002/cncy.22224. doi: 10.1002/cncy.22224 pmid: 31821747
[17]	Aghajani MJ, Roberts TL, Yang T, et al. Elevated levels of soluble PD-L1 are associated with reduced recurrence in papillary thyroid cancer[J]. Endocr Connect, 2019, 8(7):1040-1051. DOI: 10.1530/ec-19-0210. doi: 10.1530/EC-19-0210 pmid: 31252406
[18]	Ulisse S, Tuccilli C, Sorrenti S, et al. PD-1 ligand expression in epithelial thyroid cancers: potential clinical implications[J]. Int J Mol Sci, 2019, 20(6):1405. DOI: 10.3390/ijms20061405. doi: 10.3390/ijms20061405
[19]	Gunda V, Gigliotti B, Ndishabandi D, et al. Combinations of BRAF inhibitor and anti-PD-1/PD-L1 antibody improve survival and tumour immunity in an immunocompetent model of orthotopic murine anaplastic thyroid cancer[J]. Br J Cancer, 2018, 119(10):1223-1232. DOI: 10.1038/s41416-018-0296-2. doi: 10.1038/s41416-018-0296-2
[20]	Kollipara R, Schneider B, Radovich M, et al. Exceptional response with immunotherapy in a patient with anaplastic thyroid cancer[J]. Oncologist, 2017, 22(10):1149-1151. DOI: 10.1634/theoncologist.2017-0096. doi: 10.1634/theoncologist.2017-0096 pmid: 28778959
[21]	Iyer PC, Dadu R, Gule-Monroe M, et al. Salvage pembrolizumab added to kinase inhibitor therapy for the treatment of anaplastic thyroid carcinoma[J]. J Immunother Cancer, 2018, 6(1):68. DOI: 10.1186/s40425-018-0378-y. doi: 10.1186/s40425-018-0378-y
[22]	Mehnert JM, Varga A, Brose MS, et al. Safety and antitumor activity of the anti-PD-1 antibody pembrolizumab in patients with advanced, PD-L1-positive papillary or follicular thyroid cancer[J]. BMC Cancer, 2019, 19(1):196. DOI: 10.1186/s12885-019-5380-3. doi: 10.1186/s12885-019-5380-3 pmid: 30832606
[23]	Chintakuntlawar AV, Yin J, Foote RL, et al. A phase 2 study of pembrolizumab combined with chemoradiotherapy as initial treatment for anaplastic thyroid cancer[J]. Thyroid, 2019, 29(11):1615-1622. DOI: 10.1089/thy.2019.0086. doi: 10.1089/thy.2019.0086 pmid: 31595822
[24]	Pozdeyev N, Erickson TA, Zhang L, et al. Comprehensive immune profiling of medullary thyroid cancer[J]. Thyroid, 2020, 30(9):1263-1279. DOI: 10.1089/thy.2019.0604. doi: 10.1089/thy.2019.0604 pmid: 32242507
[25]	Schlumberger M, Elisei R, Müller S, et al. Overall survival analysis of EXAM, a phase Ⅲ trial of cabozantinib in patients with radiographically progressive medullary thyroid carcinoma[J]. Ann Oncol, 2017, 28(11):2813-2819. DOI: 10.1093/annonc/mdx479. doi: S0923-7534(19)34601-0 pmid: 32014215
[26]	Shi RL, Qu N, Luo TX, et al. Programmed death-ligand 1 expre-ssion in papillary thyroid cancer and its correlation with clinicopathologic factors and recurrence[J]. Thyroid, 2017, 27(4):537-545. DOI: 10.1089/thy.2016.0228. doi: 10.1089/thy.2016.0228
[27]	Girolami I, Pantanowitz L, Mete O, et al. Programmed death-ligand 1 (PD-L1) is a potential biomarker of disease-free survival in papi-llary thyroid carcinoma: a systematic review and meta-analysis of PD-L1 immunoexpression in follicular epithelial derived thyroid carcinoma[J]. Endocr Pathol, 2020, 31(3):291-300. DOI: 10.1007/s12022-020-09630-5. doi: 10.1007/s12022-020-09630-5 pmid: 32468210
[28]	Aghajani M, Graham S, McCafferty C, et al. Clinicopathologic and prognostic significance of programmed cell death ligand 1 expression in patients with non-medullary thyroid cancer: a systematic review and meta-analysis[J]. Thyroid, 2018, 28(3):349-361. DOI: 10.1089/thy.2017.0441. doi: 10.1089/thy.2017.0441 pmid: 29455638
[29]	Rosenbaum MW, Gigliotti BJ, Pai SI, et al. PD-L1 and IDO1 are expressed in poorly differentiated thyroid carcinoma[J]. Endocr Pathol, 2018, 29(1):59-67. DOI: 10.1007/s12022-018-9514-y. doi: 10.1007/s12022-018-9514-y pmid: 29372535
[30]	Brauner E, Gunda V, Vanden Borre P, et al. Combining BRAF inhibitor and anti PD-L1 antibody dramatically improves tumor regre-ssion and anti tumor immunity in an immunocompetent murine model of anaplastic thyroid cancer[J]. Oncotarget, 2016, 7(13):17194-17211. DOI: 10.18632/oncotarget.7839. doi: 10.18632/oncotarget.7839 pmid: 26943572
[31]	Shi X, Li CW, Tan LC, et al. Immune co-inhibitory receptors PD-1, CTLA-4, TIM-3, LAG-3, and TIGIT in medullary thyroid cancers: a large cohort study[J]. J Clin Endocrinol Metab, 2021, 106(1):120-132. DOI: 10.1210/clinem/dgaa701. doi: 10.1210/clinem/dgaa701
[32]	Shi X, Yu PC, Li BW, et al. Association between programmed death-ligand 1 expression and clinicopathological characteristics, structural recurrence, and biochemical recurrence/persistent disease in medullary thyroid carcinoma[J]. Thyroid, 2019, 29(9):1269-1278. DOI: 10.1089/thy.2019.0079. doi: 10.1089/thy.2019.0079